NKGen Biotech, Inc. (NKGN)
OTCMKTS
· Delayed Price · Currency is USD
0.1400
0.00 (0.00%)
Aug 15, 2025, 1:49 PM EDT
NKGen Biotech Employees
NKGen Biotech had 63 employees as of December 31, 2023.
Employees
63
Change
n/a
Growth
n/a
Revenue / Employee
n/a
Profits / Employee
-$769,492
Market Cap
10.47M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 63 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Tian'an Technology Group | 8 |
| Glass House Brands | 374 |
| Elite Pharmaceuticals | 68 |
| American Oncology Network | 1,914 |
| Northwest Biotherapeutics | 25 |
| CytoDyn | 13 |
| Silence Therapeutics | 116 |
NKGen Biotech News
- 10 days ago - NKGen Biotech To Present on Allogeneic Enhanced NK Cells without Lymphodepletion in Solid Tumors at the 13th Annual Immuno-Oncology Summit - GlobeNewsWire
- 19 days ago - NKGen Biotech Presents Troculeucel Mechanism of Action with Corresponding Phase 1 Biomarker Data at the Alzheimer's Association International Conference 2025 - GlobeNewsWire
- 25 days ago - NKGen Biotech to Present at the Alzheimer's Association International Conference 2025 - GlobeNewsWire
- 4 weeks ago - NKGen Biotech and HekaBio Enter Strategic Partnership to Bring Novel NK Cell Therapy to Japan - GlobeNewsWire
- 4 weeks ago - NKGen Biotech Announces New Funding to Regain Compliance with Reporting Obligations and Listing Standards - GlobeNewsWire
- 5 weeks ago - NKGen Biotech Administers First Dose of Troculeucel to Alzheimer's Patient Who Continued to Decline Cognitively While on Prior Amyloid-Targeting Therapy - GlobeNewsWire
- 7 weeks ago - NKGen Biotech Announces International and U.S. Expansion of Phase 1/2a Troculeucel Alzheimer's Trial with Activation of Clinical Sites in Canada and Florida - GlobeNewsWire
- 3 months ago - NKGen Biotech Chairman & CEO Paul Y. Song, M.D. - GlobeNewsWire